Fluvastatin Inhibits Hepatitis C Replication in Humans

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Gastroenterology

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1572-0241.2008.01876.xPMID 18410471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins Improve ALT Values in Chronic Hepatitis C Patients with Abnormal Values

  2010cited by this paper
• Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell

  2007cited by this paper
• Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial

  2007cited by this paper
• The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

  2007cited by this paper
• Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism

  2007cited by this paper
• Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

  2007cited by this paper
• A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.

  2007cited by this paper
• Incidence of statin hepatotoxicity in patients with hepatitis C.

  2006cited by this paper
• Different anti‐HCV profiles of statins and their potential for combination therapy with interferon

  2006cited by this paper
• Mechanisms and significance of liver steatosis in hepatitis C virus infection.

  2006cited by this paper
• Industry, FDA warm to "adaptive" trials.

  2006cited by this paper
• Peginterferon and ribavirin for chronic hepatitis C.

  2006cited by this paper
• Hepatitis C virus particles and lipoprotein metabolism.

  2005cited by this paper
• Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.

  2005cited by this paper
• Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts.

  2004cited by this paper
• Antiviral action of ribavirin in chronic hepatitis C.

  2004cited by this paper
• Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

  2003cited by this paper
• Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

  2003cited by this paper
• Safety, Tolerability, and Pharmacokinetics of an Extended-Release Formulation of Fluvastatin Administered Once Daily to Patients with Primary Hypercholesterolemia

  2001cited by this paper
• "Breakthrough" during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management.

  1998cited by this paper
• Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.

  1997cited by this paper
• Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection.

  1996cited by this paper
• Fluctations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

  1996cited by this paper
• Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1995influential reference
• Goodman and Gilman's the pharmacologic basis of therapeutics

  1991cited by this paper
• Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.

  1990influential reference
• Pharmacokinetics and pharmacodynamics.

  1990cited by this paper
• Pharmacokinetics and pharmacodynamics.

  1979cited by this paper

• Lipid-targeting antiviral strategies: current state and future perspectives.

  2025cites this paper
• Statins in Chronic Liver Disease: Review of the Literature and Future Role

  2024cites this paper
• Exploring the potential of drug repurposing for liver diseases: A comprehensive study.

  2024cites this paper
• A Critical Assessment of COVID-19 Genomic Vaccines.

  2023cites this paper
• Chronic Hepatitis B, C, and stroke; association and pathophysiology

  2023cites this paper
• Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases

  2023cites this paper
• Lactate: A Theranostic Biomarker for Metabolic Psychiatry?

  2023cites this paper
• Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis and Systematic Review

  2022cites this paper
• Role of Lipid Rafts in Pathogen-Host Interaction - A Mini Review

  2022cites this paper
• Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice

  2022cites this paper
• Synthesis under microwaves irradiation, structure elucidation, docking study for inhibiting COVID-19 and DFT calculations of novel azoles incorporated indole moiety

  2021cites this paper
• Anti-flavivirus Properties of Lipid-Lowering Drugs

  2021cites this paper
• Coronaviruses, cholesterol and statins: Involvement and application for Covid-19

  2021cites this paper
• Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens

  2021cites this paper
• Drug discovery and development: An overview of modern methods and principles

  2021cites this paper
• Research Progress of Statins in the Treatment of Liver Diseases

  2021cites this paper
• INFLUENCE OF ANTIVIRAL THERAPY ON INDICATORS OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS

  2020influential citation
• Host-Directed Antiviral Therapy

  2020cites this paper
• Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro

  2020cites this paper
• Hepatitis C virus genotypes 1–3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes

  2020cites this paper
• Antiviral effects of statins.

  2020cites this paper
• Drug-Induced Liver Injury from Statins.

  2020cites this paper
• Hepatitis C virus NS3-4A protease regulates the lipid environment for RNA replication by cleaving host enzyme 24-dehydrocholesterol reductase

  2020cites this paper
• Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus

  2019cites this paper
• Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case Examples

  2019cites this paper
• Rh(III)-Catalyzed regio- and stereoselective bisindolylation of vinyl acetate: an efficient approach toward (E)-1,2-bis(2-indolyl)ethenes

  2018cites this paper
• Identification of potential anti‐hepatitis C virus agents targeting non structural protein 5B using computational techniques

  2018cites this paper
• Host-targeting therapies for hepatitis C virus infection: current developments and future applications

  2018cites this paper
• The potential role of statins in treating liver disease

  2018cites this paper
• Combination of Simvastatin and Entecavir for Chronic Hepatitis B : A Phase 1 Trial

  2018cites this paper
• Impact of pre-existing treatment with statins on the course and outcome of tick-borne encephalitis

  2018cites this paper
• Bioactive Products from Fungi

  2017cites this paper
• Synthesis and Antiproliferative Activity of Novel Neocryptolepine-Hydrazides Hybrids -

  2017cites this paper
• Rationale for the use of statins in liver disease.

  2017cites this paper
• Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based study

  2017cites this paper
• Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies

  2017cites this paper
• Iron‐Catalyzed Regioselective Synthesis of 3‐Arylindoles

  2017cites this paper
• Palladium(II)/N‐Heterocyclic Carbene‐Catalyzed Regioselective Heteroannulation of Tertiary Propargyl Alcohols and o‐Haloanilines to form 2‐Alkenylindoles

  2017cites this paper
• Discovery of antimicrobial compounds targeting bacterial type FAD synthetases

  2017cites this paper
• Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

  2017cites this paper
• Pleiotropic effects of statins in the diseases of the liver.

  2016cites this paper
• Short interval change in hepatitis C hypervariable region 1 in chronic infection.Are there treatment windows in the envelope

  2016cites this paper
• Effects of Interferons and Viruses on Metabolism

  2016cites this paper
• Synthesis of New Functionalized Indoles Based on Ethyl Indol-2-carboxylate

  2016cites this paper
• Statins and its hepatic effects: Newer data, implications, and changing recommendations

  2016cites this paper
• Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

  2016influential citation
• Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection

  2016cites this paper
• Production of valuable compounds by molds and yeasts

  2016cites this paper
• [Present and future of therapy against hepatitis C].

  2016cites this paper
• Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.

  2016cites this paper
• Presente y futuro de la terapia contra la hepatitis C.

  2016cites this paper
• Statins can exert dual, concentration dependent effects on HCV entry in vitro.

  2016cites this paper
• UPLC–MS method for the simultaneous determination of naproxen, fluvastatin and ibuprofen in waste water samples

  2015cites this paper
• Chapter 1 – Drug Discovery and Development: An Overview of Modern Methods and Principles

  2015cites this paper
• Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.

  2015cites this paper
• Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.

  2015cites this paper
• KO(t)Bu-mediated aerobic transition-metal-free regioselective β-arylation of indoles: synthesis of β-(2-/4-nitroaryl)-indoles.

  2015cites this paper
• Statins demonstrate a broad anti‐cytomegalovirus activity in vitro in ganciclovir‐susceptible and resistant strains

  2015influential citation
• Cholesterol Flux Is Required for Endosomal Progression of African Swine Fever Virions during the Initial Establishment of Infection

  2015cites this paper
• Effect of addition of statins to antiviral therapy in hepatitis C virus–infected persons: Results from ERCHIVES

  2015cites this paper
• Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.

  2015cites this paper
• Evaluation of fluvastatin in combination with the standard of care therapy (PEG-IFN/Ribavirin) in Egyptian patients with hepatitis C virus.

  2015cites this paper
• Review article: management of chronic hepatitis C in patients with contraindications to anti‐viral therapy

  2014cites this paper
• Finding Candidate Drugs for Hepatitis C Based on Chemical-Chemical and Chemical-Protein Interactions

  2014cites this paper
• Statin efficacy in the treatment of hepatitis C genotype I

  2014cites this paper
• Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency

  2014cites this paper
• Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin

  2014cites this paper
• Hepatitis C for Primary Care Physicians

  2014cites this paper
• Characterization of heme oxygenase 1 based therapy options in chronic persistent HCV infection

  2014influential citation
• 463-469- Mihaila

  2014cites this paper
• Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope

  2014cites this paper
• Statin use and risk of hepatocellular carcinoma in a U.S. population.

  2014cites this paper
• Facile synthesis of 2-arylmethylindoles and 2-vinylic indoles through palladium-catalyzed heteroannulations of 2-(2-propynyl)aniline and 2-(2-propynyl)tosylanilide.

  2014cites this paper
• Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?

  2014cites this paper
• Statins in Chronic Hepatitis C: Stage result.

  2014cites this paper
• Valuable Secondary Metabolites from Fungi

  2014cites this paper
• Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin.

  2014cites this paper
• Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial

  2014cites this paper
• Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro

  2014cites this paper
• Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.

  2014cites this paper
• The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis

  2014cites this paper
• Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C

  2014cites this paper
• Effects of “vitex agnus castus” extract and magnesium supplementation, alone and in combination, on osteogenic and angiogenic factors and fracture healing in women with long bone fracture

  2014cites this paper
• Biosynthesis and Molecular Genetics of Fungal Secondary Metabolites

  2014cites this paper
• Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?

  2014cites this paper
• Are statins a viable option for the treatment of infections with the hepatitis C virus?

  2014cites this paper
• Review article: prescribing medications in patients with cirrhosis – a practical guide

  2013cites this paper
• Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Naïve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3

  2013cites this paper
• STATIN THERAPY IN PATIENTS WITH DIABETES AND HEPATITIS C

  2013influential citation
• Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.

  2013cites this paper
• Reaction of Diphenacylanilines with 2-Aminobenzophenone: An Abnormal Friedlander Reaction Yielding Indoles

  2013cites this paper
• Potential role for statins in the treatment of chronic HCV infection

  2013cites this paper
• Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism

  2013cites this paper
• The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.

  2013cites this paper
• Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b

  2013cites this paper
• Add‐on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C

  2013cites this paper
• HCV and Host Lipids: An Intimate Connection

  2013cites this paper
• Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans

  2013cites this paper
• For Peer Review Fluvastatin does not exhibit an add -on effect on pegylated - interferon/ribavirin/telaprevir therapy for HCV genotype 1b-infected chronic hepatitis C

  2013cites this paper
• A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients

  2013cites this paper